Table 2.
subject characteristics by cancer cohort.
| RCC | Melanoma | Bladder | HCC | SCC | Gyn | H&N | Total | ||
|---|---|---|---|---|---|---|---|---|---|
| Number of subjects | 58 | 118 | 40 | 19 | 19 | 15 | 15 | 284 | |
| Age at first COVID vaccination (years) | Median (IQR) | 65.0 (56.2–71.5) | 64.5 (54.2–71.8) | 72.5 (66.0–79.2) | 70.0 (63.5–74.0) | 77.0 (72.0–82.5) | 67.0 (64.5 to 75.0) | 66.0 (61.5–72.0) | 67.0 (59.0 to 75.0) |
| ICI therapy type | Monotherapy | 26 (44.8) | 85 (72.0) | 37 (92.5) | 9 (47.4) | 19 (100.0) | 10 (66.7) | 15 (100.0) | 201 (70.8) |
| Combo ICI-ICI | 9 (15.5) | 31 (26.3) | 2 (5.0) | 10 (52.6) | 0 | 1 (6.7) | 0 | 53 (18.7) | |
| Combo ICI-Other | 23 (39.7) | 2 (1.7) | 1 (2.5) | 0 | 0 | 4 (26.7) | 0 | 30 (10.5) | |
| Number of COVID-19 vaccinations received | 1 | 4 (6.9) | 4 (3.4) | 2 (5.0) | 1 (5.3) | 0 | 0 | 0 | 11 (3.9) |
| 2 | 16 (27.6) | 11 (9.3) | 11 (27.5) | 8 (42.1) | 5 (26.3) | 6 (40.0) | 3 (20.0) | 60 (21.1) | |
| 3 | 37 (63.8) | 103 (87.3) | 27 (67.5) | 10 (52.6) | 14 (73.7) | 9 (60.0) | 12 (80.0) | 212 (74.6) | |
| Missing | 1 (1.7) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.4) | |
| Shortest interval between most recent ICI dose and vaccination | ≥7 days | 38 (65.5) | 74 (62.7) | 35 (87.5) | 8 (42.1) | 12 (63.2) | 7 (46.7) | 8 (53.3) | 182 (64.1) |
| <7 days | 20 (34.5) | 44 (37.3) | 5 (12.5) | 11 (57.9) | 7 (36.8) | 8 (53.3) | 7 (46.7) | 102 (35.9) |
RCC = Renal cell carcinoma.
HCC = Hepatocellular carcinoma.
SCC = Squamous cell carcinoma (skin).
Gyn = Gynecological cancers.
H&N = Head and neck cancers.
irAE = Immune-mediated adverse effect.
ICI = Immune checkpoint inhibitor.
ICI-Other = ICI plus chemotherapy or vascular endothelial growth factor receptor tyrosine kinase inhibitor or monoclonal antibody.